Fig. 6
From: SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells
siSIRT3 opposes iSGLT2-dependent cytotoxicity and mitochondrial injury. Detection of (A, H) cytotoxicity, (B, I) glucose, (C, J) lactate (D, K) ATP and (E, L) NAD+/NADH levels and cytofluorimetric detection and representative fluorescent images of (F, G and M, N) mitochondrial ROS in HCT 116 and HT-29 cells treated with 50 µM iSGLT2 for 72 h (iSGLT2) or transfected with nontargeting siRNA control (NT) or SIRT3 siRNA (siSIRT3) before exposure to iSGLT2 (NT + iSGLT2 or siSIRT3 + iSGLT2). Control cells (Ctr) were maintained in complete culture medium with the corresponding volume of HBSS-10 mM Hepes. Scale bars = 100 µm. †p < 0.01 vs. Ctr; ‡p < 0.001 vs. Ctr; *p < 0.01 vs. NT; ¶p < 0.001 vs. NT; •p < 0.05 vs. NT + iSGLT2; §p < 0.01 vs. NT + iSGLT2. Significance was determined using one-way ANOVA with Tukey post hoc test